Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Missing” Lilly Documents Under Review By Rep. Hinchey

This article was originally published in The Pink Sheet Daily

Executive Summary

The documents allegedly suggest that Lilly was aware of a link between Prozac and suicidality as early as the 1980s. Hinchey is expected to issue a statement regarding the documents by Jan. 7.

You may also be interested in...



British Medical Journal Apologizes To Lilly For Prozac Article

In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”

British Medical Journal Apologizes To Lilly For Prozac Article

In a “correction and apology,” the journal acknowledges that all allegedly “missing” documents related to Prozac and suicidality were disclosed during a 1994 product liability suit. BMJ retracts Jan. 1 statement about the documents, which it says it published “in good faith.”

Lilly Launches PR Blitz On Prozac To Dispute Journal's Safety Claims

Full-page ad in major newspapers defends Lilly's handling of "missing" Prozac safety data and urges patients not to discontinue use of antidepressant based solely on media reports. Company also questions British Medical Journal's use of adverse event reports to draw conclusions about fluoxetine's safety profile.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060995

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel